CN103598575A - 一种增加伤口愈合速度的海参咀嚼片 - Google Patents
一种增加伤口愈合速度的海参咀嚼片 Download PDFInfo
- Publication number
- CN103598575A CN103598575A CN201310491167.8A CN201310491167A CN103598575A CN 103598575 A CN103598575 A CN 103598575A CN 201310491167 A CN201310491167 A CN 201310491167A CN 103598575 A CN103598575 A CN 103598575A
- Authority
- CN
- China
- Prior art keywords
- parts
- sea cucumber
- wound healing
- radix
- chitin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000251511 Holothuroidea Species 0.000 title claims abstract description 116
- 230000029663 wound healing Effects 0.000 title claims abstract description 39
- 230000001055 chewing effect Effects 0.000 title abstract 3
- 229920002101 Chitin Polymers 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 23
- 244000189799 Asimina triloba Species 0.000 claims abstract description 20
- 235000006264 Asimina triloba Nutrition 0.000 claims abstract description 20
- 206010004542 Bezoar Diseases 0.000 claims abstract description 20
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 20
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 20
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 20
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 20
- 241000756943 Codonopsis Species 0.000 claims abstract description 20
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 20
- 244000164480 Curcuma aromatica Species 0.000 claims abstract description 20
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 20
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 20
- 229920001353 Dextrin Polymers 0.000 claims abstract description 20
- 239000004375 Dextrin Substances 0.000 claims abstract description 20
- 241000218378 Magnolia Species 0.000 claims abstract description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 20
- 235000003434 Sesamum indicum Nutrition 0.000 claims abstract description 20
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 20
- 235000019425 dextrin Nutrition 0.000 claims abstract description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 20
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 20
- 229920002472 Starch Polymers 0.000 claims abstract description 19
- 239000008107 starch Substances 0.000 claims abstract description 19
- 235000019698 starch Nutrition 0.000 claims abstract description 19
- 239000004863 Frankincense Substances 0.000 claims abstract description 17
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 17
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 17
- 239000003765 sweetening agent Substances 0.000 claims abstract description 17
- 244000000231 Sesamum indicum Species 0.000 claims abstract 5
- 235000016811 Biondella Nutrition 0.000 claims description 19
- 240000005250 Chrysanthemum indicum Species 0.000 claims description 19
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims description 19
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 19
- 240000002924 Platycladus orientalis Species 0.000 claims description 19
- 241001530209 Swertia Species 0.000 claims description 19
- 239000007910 chewable tablet Substances 0.000 claims description 19
- 235000009508 confectionery Nutrition 0.000 claims description 17
- 235000013599 spices Nutrition 0.000 claims description 17
- 244000170916 Paeonia officinalis Species 0.000 claims 4
- 239000003814 drug Substances 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000003832 immune regulation Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241001233914 Chelidonium majus Species 0.000 abstract 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 abstract 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 241001071795 Gentiana Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 240000003243 Thuja occidentalis Species 0.000 abstract 1
- 235000008109 Thuja occidentalis Nutrition 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 55
- 206010052428 Wound Diseases 0.000 description 32
- 208000027418 Wounds and injury Diseases 0.000 description 32
- 239000000843 powder Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 239000004365 Protease Substances 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000000284 extract Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 108091005804 Peptidases Proteins 0.000 description 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 16
- 235000019419 proteases Nutrition 0.000 description 16
- 241000736199 Paeonia Species 0.000 description 15
- 241000207961 Sesamum Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 12
- 230000002255 enzymatic effect Effects 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 9
- 108010004032 Bromelains Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 235000019835 bromelain Nutrition 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 238000000227 grinding Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 7
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 7
- -1 Rhizoma Sparganii Substances 0.000 description 7
- 230000035611 feeding Effects 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 206010039509 Scab Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000000748 compression moulding Methods 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 238000005213 imbibition Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000001728 nano-filtration Methods 0.000 description 4
- 235000011837 pasties Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 241000965254 Apostichopus japonicus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 229930188089 Holothurin Natural products 0.000 description 2
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 2
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000022972 amelogenesis Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000013860 dentinogenesis Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- MAWWITJOQDJRJF-ADBICINLSA-M holothurin Chemical compound [Na+].O[C@@H]1[C@@H](OC)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H](OC[C@H]([C@@H]3O)OS([O-])(=O)=O)O[C@@H]3C([C@H]4[C@](C=5[C@H]([C@@]6(CC[C@]7(O)[C@](C)([C@H]8OC(C)(C)CC8)OC(=O)[C@@]76[C@@H](O)C=5)C)CC4)(C)CC3)(C)C)O[C@@H]2C)O)O[C@H](C)[C@H]1O MAWWITJOQDJRJF-ADBICINLSA-M 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- SQFDQLBYJKFDDO-UHFFFAOYSA-K merbromin Chemical compound [Na+].[Na+].C=12C=C(Br)C(=O)C=C2OC=2C([Hg]O)=C([O-])C(Br)=CC=2C=1C1=CC=CC=C1C([O-])=O SQFDQLBYJKFDDO-UHFFFAOYSA-K 0.000 description 1
- 229940008716 mercurochrome Drugs 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种增加伤口愈合速度的海参咀嚼片,其中,包括按照重量份数配置的如下活性组分:中药料:莪术30-50份,三棱20-40份,乳香20-40份,柏子仁20-40份,牛黄10-30份,党参10-30份,当归10-30份,白芍10-30份,芝麻10-30份,厚朴10-30份,木瓜10-30份,白薇10-30份,野菊花10-30份,龙胆草10-30份,基础料:海参300-500份;附加料:甲壳素3-6份、淀粉10-20份、糊精5-10份、甘露醇3-6份,甜味剂1-4份,微晶纤维素1-4份。本发明配比简单,组方搭配合理,促进免疫调解、增加伤口愈合速度。
Description
技术领域:
本发明涉及海参深加工技术领域,尤其涉及一种增加伤口愈合速度的海参咀嚼片。
背景技术:
海参含胆固醇极低,为一种典型的高蛋白、低脂肪、低胆固醇食物。加上其肉质细嫩,易于消化,所以,非常适宜于老年人、儿童以及体质虚弱的人食用。海参因含胆固醇极低,为一种典型的高蛋白、低脂肪、低胆固醇的食物。又因肉质细嫩,易于消化,所以非常适合老年人与儿童,以及体质虚弱者食用。海参中的牛磺酸、尼克酸等,具有调节神经系统、快速消除疲劳,预防皮肤老化的功效,另外海参中含有的牛磺酸、赖氨酸、蛋氨酸等在植物性食品中几乎没有,刺参中含有的硫酸软骨素和刺参粘多糖,通过药理实验证明,对人体的生长发育、抗炎成骨和预防组织老化,促进伤口愈合抑制数种癌细胞都有特殊功效。延续衰老,消除疲劳,提高免疫力,增强抵抗疾病的能力 海参富含蛋白质、矿物质、维生素等50多种天然珍贵活性物质,其中酸性粘多糖和软骨素可明显降低心脏组织中脂褐素和皮肤脯氨酸的数量,起到延缓衰老的作用。海参体内所含的18种氨基酸能够增强组织的代谢功能,增强机体细胞活力,适宜于生长发育中的青少年。海参能调节人体水份平衡,适宜于孕期腿脚浮肿的女士。海参能消除疲劳,提高人体免疫力,增强人体抵抗疾病的能力,因此非常适合经常处于疲劳状态的中年女士与男士,易感冒、体质虚弱的老年人和儿童等亚健康人群。
海参的其他功用,如消除肿瘤、抗癌护心脏:在海参的体壁、内脏和腺体等组织中含有大量的海参毒素,又叫海参皂甙。海参毒素是一种抗毒剂,对人体安全无毒,但能抑制肿瘤细胞的生长与转移,有效防癌、抗癌,临床上已广泛应用于肝癌、肺癌、胃癌、鼻咽癌、骨癌、淋巴癌、卵巢癌、子宫癌、乳腺癌、脑癌白血病及手术后患者的治疗。改善骨质疏松经常食用海参可以预防儿童的佝偻病、成人的骨质疏松症和骨质增生症。金至尊海参中丰富的钙、磷、锰、铜、锗、硅等元素对预防婴儿佝偻病,成人的骨质疏松症以及对骨骼异常、畸形,牙质及釉质发育不良都有特殊作用。促进生长发育 食用海参有助于促进生长发育。海参中丰富的精氨酸、赖氨酸、牛磺酸、钙、磷、碘、铁、锌,是人体发育成长的重要物质,它们直接参与人体本身的生长发育、免疫调解、伤口愈合、生殖发育等生理活动,在人体能量储备和运转中起着重要作用,因此,作为术后的营养品,海参可以大大加快伤口的愈合速度。
在日常生活和医疗中,创伤是在所难免的,如外伤、手术等都可引起一定的创伤。由于创伤愈合的状况与病情的发展密切相关,故创伤愈合成为现今医学研究中重要的热点之一。近年来,中草药逐渐受到人们的青睐,中医药事业正在茁壮发展,中草药促创伤愈合的研究也不断涌现。现就对中草药促进创伤愈合的作用及机制综述如下。中医对创伤愈合的认识 《正体类要》注曰:“肢体损于外,则气血伤于内,营卫有所不贯,脏腑由之不和。”指出机体创伤后气血失养、营卫失和导致气血凝滞、经络阻塞、脏腑功能失调。创面的气血盛衰、营卫强弱对创面的愈合至关重要,故活血化瘀、行气通络是治疗创伤的关键。中医学认为,创伤是由外因导致的,“伤”是在皮肤表层、程度较浅,而“创”指金属利刃导致的损害,程度深达肌肉。无论何种外伤,都会伤及血络、脉管,出现出血、瘀血或血肿,止血、消肿、活血是治疗外伤的必不可少的步骤。中医药促进创面肉芽组织生长主要集中在祛腐生肌、祛瘀生肌和补益生肌等方面。
海参对于促进伤口愈合具有显著效果,所以,通常作为术后或创后的营养补品。目前海参的服用方法,仍然以食补为主,食补导致人体吸收率不足,而且,一些烹饪的禁忌也常常导致海参营养成分损失,如,海参不能用醋做调味品。因此,市面上出现了一些海参深加工产品,如口服液,片剂,胶囊,蜜炼丸剂等等,深加工的过程中,往往加入中成药以提高产品的吸收率或增加其他附属功能,但是,有些配方不合理,例如,海参不能与甘草配伍等等。因此,本发明旨在提供一种配比简单,组方搭配合理,促进免疫调解、增加伤口愈合速度的一种增加伤口愈合速度的海参咀嚼片。
发明内容:
本发明的目的在于克服现有技术中存在的缺点,提供一种配比简单,组方搭配合理,促进免疫调解、增加伤口愈合速度一种增加伤口愈合速度的海参咀嚼片。
为了实现上述目的,本发明提供了一种增加伤口愈合速度的海参咀嚼片,其中,包括按照重量份数配置的如下活性组分:
中药料:莪术30-50份,三棱20-40份,乳香20-40份,柏子仁20-40份,牛黄10-30份,党参10-30份,当归10-30份,白芍10-30份,芝麻10-30份,厚朴10-30份,木瓜10-30份,白薇10-30份,野菊花10-30份,龙胆草10-30份,
基础料:海参300-500份;
附加料:甲壳素3-6份、淀粉10-20份、糊精5-10份、甘露醇3-6份,甜味剂1-4份,微晶纤维素1-4份。
或者,包括按照重量份数配置的如下活性组分:
中药料:莪术30-40份,三棱20-30份,乳香20-30份,柏子仁20-30份,牛黄10-20份,党参10-20份,当归10-20份,白芍10-20份,芝麻10-20份,厚朴10-20份,木瓜10-20份,白薇10-20份,野菊花10-20份,龙胆草10-20份,
基础料:海参300-400份;
附加料:甲壳素3-5份,淀粉10-15份、糊精5-8份、甘露醇3-5份,甜味剂1-3份,微晶纤维素1-3份。
或者,包括按照重量份数配置的如下活性组分:
中药料:莪术40-50份,三棱30-40份,乳香30-40份,柏子仁30-40份,牛黄20-30份,党参20-30份,当归20-30份,白芍20-30份,芝麻20-30份,厚朴20-30份,木瓜20-30份,白薇20-30份,野菊花20-30份,龙胆草20-30份,
基础料:海参400-500份;
附加料:甲壳素4-6份,淀粉15-20份、糊精8-10份、甘露醇4-6份,甜味剂2-4份,微晶纤维素2-4份。
或者,包括按照重量份数配置的如下活性组分:
中药料:中药料:莪术35-45份,三棱25-35份,乳香25-35份,柏子仁25-35份,牛黄15-25份,党参15-25份,当归15-25份,白芍15-25份,芝麻15-25份,厚朴15-25份,木瓜15-25份,白薇15-25份,野菊花15-25份,龙胆草15-25份,
基础料:海参350-450份;
附加料:甲壳素4-5份,淀粉12-18份、糊精6-9份、甘露醇2-5份,甜味剂2-3份,微晶纤维素2-3份。
为更好的实现本发明的目的,本发明又公开了增加伤口愈合速度的海参咀嚼片的制备方法,其中,包括如下步骤:
A、清洗的步骤:将莪术,三棱,乳香,柏子仁,牛黄,党参,当归,白芍,芝麻,厚朴,木瓜,白薇,野菊花,龙胆草,使用滚筒式洗药机进行清洗,清洗时间控制在3-5分钟,避免药效流失;
B、润药的步骤:将步骤A清洗干净的中药组分,使用注水式润药机进行润药操作,润药使失水的植物细胞吸水膨胀,为提取工序创造条件;
C、上述组份加重量10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08;所述滤液流经体积为10L的大孔吸附树脂柱,之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到中药药粉,再经80目筛子过筛后,经紫外线杀菌后备用;
D、海参深加工的步骤:鲜活海参,沿腹部从头至尾全剖开,去除内脏,将杂质清洗干净;接着进行冷冻干燥,冷冻温度为-20~-25℃,真空度为5-15Pa,快速冷冻2-3h,将冷冻干燥后的海参放入粉碎机,粉碎10-30min,过60 目筛,得到粗海参粉;将海参粗粉通过气流粉碎机进行超微粉碎,时间2-3h,得到超微海参粉;然后将超微海参粉通过高速剪切超细粉碎机进行纳米化粉碎,粉碎时间为3-5h;
向容器中加入纯净水,使纳米化粉碎后的海参粉与水以1 :5-10 质量比溶解,得到海参浆,称取海参重量0.3-0.4% 的复合蛋白酶,复合蛋白酶为胃蛋白酶的菠萝酶胃的混合物,蛋白酶:菠萝酶的质量比=2:1,使用纯净水将复合蛋白酶溶化后,连同海参浆一起放入酶解罐中,在强度为500-1000w 的微波环境中静置1-2min,进行微波酶解作业,酶解完成后,将酶解液迅速升温度至90℃灭酶10-30min ;完成酶的灭活后,对酶解罐停止加热,将酶解液迅速冷却至常温;酶解罐用纯净水冲洗,冲洗液放入酶解液中;将降温后的酶解液先用普通离心机离心20min,过滤;取滤液,低温超高速离心20min,过滤,得滤液;将滤液通过纳滤以除去盐分;剩余物过100 目筛,得到海参提取液;
E、制备胶囊的步骤:将步骤C所得中药药粉加入到步骤D所得的海参提取液中,中药药粉:海参提取液的重量比为1-1.2:1-1.5;混合均匀后,加入附加料,得到的混合物呈糊状,压片成型,干燥得咀嚼片。
附加料中的成分如下:
甲壳素(即甲壳质)的医理作用如下:1、外伤止血,血小板与血液中的甲壳质结合,能提高创伤组织的粘附力,快速使局部血管收缩,降低出血数量。2、提高伤口愈合速度,新的组织细胞的增殖、形成急需多量的基础物质,透明质酸是重要的材料。甲壳质能增加组织中透明质酸的数量,促进细胞膜的形成。并在活化细胞过程中,产生大量胶原纤维,迅速形成密质皮肤,不会留下疤痕。3、甲壳质能够防治创伤面感染,甲壳质外用在创伤局部可抑制细菌生长,国内外文献报告甲壳质敷在体外伤口能够抑制革兰氏阳性菌和白念珠菌生长,5 mg/ml抑菌率达75~100%;可增加创伤局部吞噬细胞的数量和活性;及时消除坏死组织,促进肉芽组织的形成。构成创伤口愈合的这三大要素,相辅相成综合起作用。4、甲壳质在骨外科上的应用,甲壳质做为骨缺损部填充物,由于帮助血小板粘附加速凝集显示良好的止血作用,在甲壳质的周围聚集多量的吞噬细胞、巨噬细胞,抑制局部病原菌的侵袭具有明显的加速骨修复的作用。
淀粉 :比较常用的是玉米淀粉,它的性质非常稳定,与大多数药物不起作用,价格也比较便宜,吸湿性小、外观色泽好,在实际生产中,常与可压性较好的糖粉、糊精混合使用,这是因为淀粉的可压性较差,若单独使用,会使压出的药片过于松散。
糊精:糊精是淀粉水解中间产物的总称,其化学式为(C6H10O5)n·XH2O,其水溶物约为80%,在冷水中溶解较慢,较易溶于热水,不溶于乙醇。习惯上亦称其为为高糊(高粘度糊精),即具有较强的粘结性。
微晶纤维素:微晶纤维素(Microcrystalline cellulose, MCC)是纤维素部分水解而制得的聚合度较小的结晶性纤维素,具有良好的可压性,有较强的结合力,压成的片剂有较大有硬度,可作为粉末直接压片的“干粘合剂”使用。
甘露醇:甘露醇呈颗粒或粉末状,在口中溶解时吸热,因而有凉爽感,同时兼具一定的甜味,在口中无砂砾感,因此较适于制备咀嚼片。
甜味剂(优选糖粉):糖粉系指结晶性蔗糖经低温干燥粉碎后而成的白色粉末,其优点在于粘合力强,可用来增加片剂的硬度,并使片剂的表面光滑美观。
本发明的优点为:配比简单,组方搭配合理,促进免疫调解、增加伤口愈合速度,具体为:
本发明以海参为基础料,在其中加入活血化瘀,止血止痛,行气通络,清热润燥的相应中药组分,以提高伤口愈合速度,另外,进一步添加甲壳素,使海参功效、中药功效与甲壳素功效相结合,制备成为咀嚼片使用,较单独的中药治疗、单纯的海参食补或者甲壳素胶丸在治疗伤口的速度上均效果显著。
具体实施方式:
增加伤口愈合速度的海参咀嚼片,其中,包括按照重量份数配置的如下活性组分:
中药料:莪术30-50份,三棱20-40份,乳香20-40份,柏子仁20-40份,牛黄10-30份,党参10-30份,当归10-30份,白芍10-30份,芝麻10-30份,厚朴10-30份,木瓜10-30份,白薇10-30份,野菊花10-30份,龙胆草10-30份,
基础料:海参300-500份;
附加料:甲壳素3-6份、淀粉10-20份、糊精5-10份、甘露醇3-6份,甜味剂1-4份,微晶纤维素1-4份。
或者,包括按照重量份数配置的如下活性组分:
中药料:莪术30-40份,三棱20-30份,乳香20-30份,柏子仁20-30份,牛黄10-20份,党参10-20份,当归10-20份,白芍10-20份,芝麻10-20份,厚朴10-20份,木瓜10-20份,白薇10-20份,野菊花10-20份,龙胆草10-20份,
基础料:海参300-400份;
附加料:甲壳素3-5份,淀粉10-15份、糊精5-8份、甘露醇3-5份,甜味剂1-3份,微晶纤维素1-3份。
或者,包括按照重量份数配置的如下活性组分:
中药料:莪术40-50份,三棱30-40份,乳香30-40份,柏子仁30-40份,牛黄20-30份,党参20-30份,当归20-30份,白芍20-30份,芝麻20-30份,厚朴20-30份,木瓜20-30份,白薇20-30份,野菊花20-30份,龙胆草20-30份,
基础料:海参400-500份;
附加料:甲壳素4-6份,淀粉15-20份、糊精8-10份、甘露醇4-6份,甜味剂2-4份,微晶纤维素2-4份。
或者,包括按照重量份数配置的如下活性组分:
中药料:中药料:莪术35-45份,三棱25-35份,乳香25-35份,柏子仁25-35份,牛黄15-25份,党参15-25份,当归15-25份,白芍15-25份,芝麻15-25份,厚朴15-25份,木瓜15-25份,白薇15-25份,野菊花15-25份,龙胆草15-25份,
基础料:海参350-450份;
附加料:甲壳素4-5份,淀粉12-18份、糊精6-9份、甘露醇2-5份,甜味剂2-3份,微晶纤维素2-3份。
具体例子1
中药料:莪术50份,三棱40份,乳香40份,柏子仁40份,牛黄30份,党参30份,当归30份,白芍30份,芝麻30份,厚朴30份,木瓜30份,白薇30份,野菊花30份,龙胆草30份,
基础料:海参500份;
附加料:甲壳素6份、淀粉20份、糊精10份、甘露醇6份,甜味剂4份,微晶纤维素4份。
制备时,A、清洗的步骤:将莪术,三棱,乳香,柏子仁,牛黄,党参,当归,白芍,芝麻,厚朴,木瓜,白薇,野菊花,龙胆草,使用滚筒式洗药机进行清洗,清洗时间控制在3-5分钟,避免药效流失;
B、润药的步骤:将步骤A清洗干净的中药组分,使用注水式润药机进行润药操作,润药使失水的植物细胞吸水膨胀,为提取工序创造条件;
C、上述组份加重量10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08;所述滤液流经体积为10L的大孔吸附树脂柱,之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到中药药粉,再经80目筛子过筛后,经紫外线杀菌后备用;
D、海参深加工的步骤:鲜活海参,沿腹部从头至尾全剖开,去除内脏,将杂质清洗干净;接着进行冷冻干燥,冷冻温度为-20~-25℃,真空度为5-15Pa,快速冷冻2-3h,将冷冻干燥后的海参放入粉碎机,粉碎10-30min,过60 目筛,得到粗海参粉;将海参粗粉通过气流粉碎机进行超微粉碎,时间2-3h,得到超微海参粉;然后将超微海参粉通过高速剪切超细粉碎机进行纳米化粉碎,粉碎时间为3-5h;
向容器中加入纯净水,使纳米化粉碎后的海参粉与水以1 :5-10 质量比溶解,得到海参浆,称取海参重量0.3-0.4% 的复合蛋白酶,复合蛋白酶为胃蛋白酶的菠萝酶胃的混合物,蛋白酶:菠萝酶的质量比=2:1,使用纯净水将复合蛋白酶溶化后,连同海参浆一起放入酶解罐中,在强度为500-1000w 的微波环境中静置1-2min,进行微波酶解作业,酶解完成后,将酶解液迅速升温度至90℃灭酶10-30min ;完成酶的灭活后,对酶解罐停止加热,将酶解液迅速冷却至常温;酶解罐用纯净水冲洗,冲洗液放入酶解液中;将降温后的酶解液先用普通离心机离心20min,过滤;取滤液,低温超高速离心20min,过滤,得滤液;将滤液通过纳滤以除去盐分;剩余物过100 目筛,得到海参提取液;
E、制备胶囊的步骤:将步骤C所得中药药粉加入到步骤D所得的海参提取液中,中药药粉:海参提取液的重量比为1-1.2:1-1.5;混合均匀后,加入附加料,得到的混合物呈糊状,压片成型,干燥得咀嚼片。
具体例子2
中药料:莪术30份,三棱20份,乳香20份,柏子仁20份,牛黄10份,党参10份,当归10份,白芍10份,芝麻10份,厚朴10份,木瓜10份,白薇10份,野菊花10份,龙胆草10份,
基础料:海参300份;
附加料:甲壳素3份、淀粉10份、糊精5份、甘露醇3份,甜味剂1份,微晶纤维素1份。
制备时,A、清洗的步骤:将莪术,三棱,乳香,柏子仁,牛黄,党参,当归,白芍,芝麻,厚朴,木瓜,白薇,野菊花,龙胆草,使用滚筒式洗药机进行清洗,清洗时间控制在3-5分钟,避免药效流失;
B、润药的步骤:将步骤A清洗干净的中药组分,使用注水式润药机进行润药操作,润药使失水的植物细胞吸水膨胀,为提取工序创造条件;
C、上述组份加重量10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08;所述滤液流经体积为10L的大孔吸附树脂柱,之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到中药药粉,再经80目筛子过筛后,经紫外线杀菌后备用;
D、海参深加工的步骤:鲜活海参,沿腹部从头至尾全剖开,去除内脏,将杂质清洗干净;接着进行冷冻干燥,冷冻温度为-20~-25℃,真空度为5-15Pa,快速冷冻2-3h,将冷冻干燥后的海参放入粉碎机,粉碎10-30min,过60 目筛,得到粗海参粉;将海参粗粉通过气流粉碎机进行超微粉碎,时间2-3h,得到超微海参粉;然后将超微海参粉通过高速剪切超细粉碎机进行纳米化粉碎,粉碎时间为3-5h;
向容器中加入纯净水,使纳米化粉碎后的海参粉与水以1 :5-10 质量比溶解,得到海参浆,称取海参重量0.3-0.4% 的复合蛋白酶,复合蛋白酶为胃蛋白酶的菠萝酶胃的混合物,蛋白酶:菠萝酶的质量比=2:1,使用纯净水将复合蛋白酶溶化后,连同海参浆一起放入酶解罐中,在强度为500-1000w 的微波环境中静置1-2min,进行微波酶解作业,酶解完成后,将酶解液迅速升温度至90℃灭酶10-30min ;完成酶的灭活后,对酶解罐停止加热,将酶解液迅速冷却至常温;酶解罐用纯净水冲洗,冲洗液放入酶解液中;将降温后的酶解液先用普通离心机离心20min,过滤;取滤液,低温超高速离心20min,过滤,得滤液;将滤液通过纳滤以除去盐分;剩余物过100 目筛,得到海参提取液;
E、制备胶囊的步骤:将步骤C所得中药药粉加入到步骤D所得的海参提取液中,中药药粉:海参提取液的重量比为1-1.2:1-1.5;混合均匀后,加入附加料,得到的混合物呈糊状,压片成型,干燥得咀嚼片。
具体例子3
中药料:莪术40份,三棱30份,乳香30份,柏子仁30份,牛黄20份,党参20份,当归20份,白芍20份,芝麻20份,厚朴20份,木瓜20份,白薇20份,野菊花20份,龙胆草20份,
基础料:海参400份;
附加料:甲壳素5份,淀粉15份、糊精8份、甘露醇5份,甜味剂3份,微晶纤维素3份。
制备时,A、清洗的步骤:将莪术,三棱,乳香,柏子仁,牛黄,党参,当归,白芍,芝麻,厚朴,木瓜,白薇,野菊花,龙胆草,使用滚筒式洗药机进行清洗,清洗时间控制在3-5分钟,避免药效流失;
B、润药的步骤:将步骤A清洗干净的中药组分,使用注水式润药机进行润药操作,润药使失水的植物细胞吸水膨胀,为提取工序创造条件;
C、上述组份加重量10倍量乙醇,加热回流提取3次,每次2小时,将3次提取液合并,减压回收乙醇,并浓缩至药液浓度为0.5g生药/mL,抽滤后,滤液的相对密度为20℃时1.08;所述滤液流经体积为10L的大孔吸附树脂柱,之后用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除乙醇溶剂,得到中药药粉,再经80目筛子过筛后,经紫外线杀菌后备用;
D、海参深加工的步骤:鲜活海参,沿腹部从头至尾全剖开,去除内脏,将杂质清洗干净;接着进行冷冻干燥,冷冻温度为-20~-25℃,真空度为5-15Pa,快速冷冻2-3h,将冷冻干燥后的海参放入粉碎机,粉碎10-30min,过60 目筛,得到粗海参粉;将海参粗粉通过气流粉碎机进行超微粉碎,时间2-3h,得到超微海参粉;然后将超微海参粉通过高速剪切超细粉碎机进行纳米化粉碎,粉碎时间为3-5h;
向容器中加入纯净水,使纳米化粉碎后的海参粉与水以1 :5-10 质量比溶解,得到海参浆,称取海参重量0.3-0.4% 的复合蛋白酶,复合蛋白酶为胃蛋白酶的菠萝酶胃的混合物,蛋白酶:菠萝酶的质量比=2:1,使用纯净水将复合蛋白酶溶化后,连同海参浆一起放入酶解罐中,在强度为500-1000w 的微波环境中静置1-2min,进行微波酶解作业,酶解完成后,将酶解液迅速升温度至90℃灭酶10-30min ;完成酶的灭活后,对酶解罐停止加热,将酶解液迅速冷却至常温;酶解罐用纯净水冲洗,冲洗液放入酶解液中;将降温后的酶解液先用普通离心机离心20min,过滤;取滤液,低温超高速离心20min,过滤,得滤液;将滤液通过纳滤以除去盐分;剩余物过100 目筛,得到海参提取液;
E、制备胶囊的步骤:将步骤C所得中药药粉加入到步骤D所得的海参提取液中,中药药粉:海参提取液的重量比为1-1.2:1-1.5;混合均匀后,加入附加料,得到的混合物呈糊状,压片成型,干燥得咀嚼片。
本发明的食用效果比较:
以50只小白鼠为实验动物,将50只小白鼠的后大腿割伤长3mm、深1mm的伤口,各抹红药水包上纱布,然后每10只为一组,
第一组为实验组喂食本发明,
第二组作为对照组1,不喂。
第三组作为对照组2,喂食步骤C所得中药药粉。
第三组作为对照组3,喂食含有甲壳质的胶丸。
第四组作为对照组4,喂食步骤D所得的海参提取液。
第五组作为对照组5,直接喂食海参。
3周后对伤口进行大体标本观察、生物力学测试,大体标本观察结果:实验组伤口完全愈合,自然掉痂;
对照组1,未愈合。完全愈合较实验组晚12天
对照组2,基本愈合,未掉痂;完全愈合较实验组晚5天
对照组3,基本愈合,未掉痂;完全愈合较实验组晚7天
对组照4,基本愈合,未掉痂;完全愈合较实验组晚6天
对照组5,未愈合,完全愈合较实验组晚10天
生物力学测试结果如下表:
从上表中可以看出,本发明具有快速愈合伤口的作用。
免疫力比较:
选10只小白鼠喂食传统增加伤口愈合速度的海参咀嚼片作为对照组,
选10只小白鼠喂食本发明作为比较组。
比较如下:
其中,比较组钙及矿物质的吸收快,增殖双歧杆菌、乳酸菌数目多,血脂、血糖、调节胆固醇的指标较对照组的低。3-5日内反复置于阴暗环境与暴晒环境,对照组染病几率大,所以,比较组免疫力强。
本发明中中药组合物对于促进伤口愈合的药学机理证据:
1、下调HIF-1α水平、上调VEGF的表达水平 ,组织细胞在缺血缺氧环境下可诱导产生缺氧诱导因子-1(hypoxia-inducible factor-1,HIF-1,包含HIF-1α和HIF-1β两种),其中HIF-1α可以调控血管内皮生长因子(vascular endothelial growth factor ,VEGF)、内皮素-1、促红细胞生成素等的表达,促进新生血管的形成和血管重构,从而启动创面修复机制。通过观察益气化瘀中药促进糖尿病皮肤溃疡大鼠缺氧诱导因子-1和血管内皮细胞生长因子的影响,结果表明益气化瘀中药可通过下调HIF-1α的表达水平、上调VEGF的表达水平,改善局部缺血缺氧状态,促使血管新生,从而促进创面愈合。
2 、增强创伤愈合中的受体RTK活性 在创伤愈合的过程中,生长因子起重要作用,而生长因子则是通过受体酪氨酸激酶(receptor tyrosine kinase, RTK)介导细胞外刺激信号,调控细胞的增殖、分化等功能。观察中药对软组织创伤愈合受体酪氨酸激酶活性的影响,结果表明中药可以增强软组织创伤愈合中的RTK活性。
3 、促进新生毛细血管的增殖,促进肉芽组织生长 改善创面血管的通透性及血管的再生,可以改善患部的血供,促进肉芽组织生长,加快创面的早期愈合。复方中药促进家兔皮肤创伤愈合的实验研究,结果表明该复方中药在创伤愈合中有显著的作用,能促进伤口血管重建,减少炎症细胞的浸润,加速胶原纤维增生形成瘢痕,防止伤口感染。
4、促进TGF-β1表达的升高 转化生长因子-β1 (transforming growth factor-β1,TGF-β1)的主要作用是调节细胞的生长和分化,诱导细胞外基质的合成及细胞凋亡,从而促进创伤的愈合。通过对转化生长因子-β与创伤愈合的观察,结果表明TGF-β1在早中期表达升高,对促进成纤维细胞合成胶原蛋白、蛋白聚糖、纤维联接蛋白和整合蛋白,增强上皮细胞迁移与成纤维细胞合成细胞外基质有关键性作用,是其促进创面愈合的一个重要方面。
本发明配比简单,组方搭配合理,促进免疫调解、增加伤口愈合速度,具体为:本发明以海参为基础料,在其中加入活血化瘀,止血止痛,行气通络,清热润燥的相应中药组分,以提高伤口愈合速度,另外,进一步添加甲壳素,使海参功效、中药功效与甲壳素功效相结合,制备成为咀嚼片使用,较单独的中药治疗、单纯的海参食补或者甲壳素胶丸在治疗伤口的速度上均效果显著。
Claims (4)
1.一种增加伤口愈合速度的海参咀嚼片,其特征在于,包括按照重量份数配置的如下活性组分:
中药料:莪术30-50份,三棱20-40份,乳香20-40份,柏子仁20-40份,牛黄10-30份,党参10-30份,当归10-30份,白芍10-30份,芝麻10-30份,厚朴10-30份,木瓜10-30份,白薇10-30份,野菊花10-30份,龙胆草10-30份,
基础料:海参300-500份;
附加料:甲壳素3-6份、淀粉10-20份、糊精5-10份、甘露醇3-6份,甜味剂1-4份,微晶纤维素1-4份。
2.根据权利要求1所述增加伤口愈合速度的海参咀嚼片,其特征在于,包括按照重量份数配置的如下活性组分:
中药料:莪术30-40份,三棱20-30份,乳香20-30份,柏子仁20-30份,牛黄10-20份,党参10-20份,当归10-20份,白芍10-20份,芝麻10-20份,厚朴10-20份,木瓜10-20份,白薇10-20份,野菊花10-20份,龙胆草10-20份,
基础料:海参300-400份;
附加料:甲壳素3-5份,淀粉10-15份、糊精5-8份、甘露醇3-5份,甜味剂1-3份,微晶纤维素1-3份。
3.根据权利要求1所述增加伤口愈合速度的海参咀嚼片,其特征在于,包括按照重量份数配置的如下活性组分:
中药料:莪术40-50份,三棱30-40份,乳香30-40份,柏子仁30-40份,牛黄20-30份,党参20-30份,当归20-30份,白芍20-30份,芝麻20-30份,厚朴20-30份,木瓜20-30份,白薇20-30份,野菊花20-30份,龙胆草20-30份,
基础料:海参400-500份;
附加料:甲壳素4-6份,淀粉15-20份、糊精8-10份、甘露醇4-6份,甜味剂2-4份,微晶纤维素2-4份。
4.根据权利要求1所述增加伤口愈合速度的海参咀嚼片,其特征在于,包括按照重量份数配置的如下活性组分:
中药料:莪术35-45份,三棱25-35份,乳香25-35份,柏子仁25-35份,牛黄15-25份,党参15-25份,当归15-25份,白芍15-25份,芝麻15-25份,厚朴15-25份,木瓜15-25份,白薇15-25份,野菊花15-25份,龙胆草15-25份,
基础料:海参350-450份;
附加料:甲壳素4-5份,淀粉12-18份、糊精6-9份、甘露醇2-5份,甜味剂2-3份,微晶纤维素2-3份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310491167.8A CN103598575A (zh) | 2013-10-20 | 2013-10-20 | 一种增加伤口愈合速度的海参咀嚼片 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310491167.8A CN103598575A (zh) | 2013-10-20 | 2013-10-20 | 一种增加伤口愈合速度的海参咀嚼片 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103598575A true CN103598575A (zh) | 2014-02-26 |
Family
ID=50116889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310491167.8A Pending CN103598575A (zh) | 2013-10-20 | 2013-10-20 | 一种增加伤口愈合速度的海参咀嚼片 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103598575A (zh) |
-
2013
- 2013-10-20 CN CN201310491167.8A patent/CN103598575A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103610035A (zh) | 一种海参营养口服液的制造方法 | |
CN103610072A (zh) | 一种降血糖海参口服液的制造方法 | |
CN103598593A (zh) | 一种海参营养片的制造方法 | |
CN103598623A (zh) | 一种海参片剂的制造方法 | |
CN103610077A (zh) | 一种海参胶囊 | |
CN103585456A (zh) | 一种海参咀嚼片 | |
CN103599468A (zh) | 一种调节免疫力的海参片剂的制造方法 | |
CN103598576A (zh) | 一种增加伤口愈合速度的海参咀嚼片的制造方法 | |
CN103598578A (zh) | 一种海参咀嚼片及其使用方法 | |
CN103598622A (zh) | 一种海参营养片及其使用方法 | |
CN103598625A (zh) | 一种海参片剂 | |
CN103599469A (zh) | 一种增加伤口愈合速度的海参咀嚼片及其使用方法 | |
CN103599366A (zh) | 一种海参咀嚼片的制造方法 | |
CN103610069A (zh) | 一种降血糖海参口服液 | |
CN103610068A (zh) | 一种降血脂海参口服液的制造方法 | |
CN103598575A (zh) | 一种增加伤口愈合速度的海参咀嚼片 | |
CN103598624A (zh) | 一种海参片剂及其使用方法 | |
CN103610116A (zh) | 一种海参营养胶囊的制造方法 | |
CN103598577A (zh) | 一种海参营养片 | |
CN103610112A (zh) | 一种增强免疫力的海参口服液及其使用方法 | |
CN107596277A (zh) | 一种增加伤口愈合速度的海参咀嚼片 | |
CN103599470A (zh) | 一种调节免疫力的海参片剂 | |
CN103610071A (zh) | 一种降血压海参口服液的制造方法 | |
CN103610070A (zh) | 一种降血脂海参口服液及其使用方法 | |
CN103610117A (zh) | 一种海参营养口服液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140226 |